What it is: A synthetic fragment of thymosin beta-4, a naturally occurring protein found in virtually every cell that plays a central role in actin regulation and tissue repair.
Research suggests: Preclinical studies show improved healing of tendons, ligaments, muscles, and cardiac tissue; some observational data from sports medicine supports the preclinical findings.
Best for: Tissue repair and recovery researchers
Key thing to know: TB-500 is a specific active fragment of the full thymosin beta-4 protein; naturally present in wound fluids and platelets, which provides biological plausibility for its repair activity.
What is TB-500?
TB-500 is a synthetic analog of Thymosin Beta-4 , a naturally occurring protein found in virtually every cell of the human body. Thymosin Beta-4 plays a central role in actin regulation: actin is the protein that gives cells their internal structure and enables them to move, divide, and repair themselves. TB-500 is a specific active fragment of Thymosin Beta-4 that researchers have isolated and studied for its potential role in tissue repair and regeneration, independent of the full protein.
Researchers have studied TB-500 primarily for wound healing, angiogenesis (new blood vessel formation), reduction of inflammation, cardiac tissue repair, and musculoskeletal recovery , primarily in preclinical studies and in equine sports medicine research. It is one of the compounds most commonly studied alongside BPC-157 in recovery-focused research protocols.
How it works.
Thymosin Beta-4 regulates actin , the structural protein that forms the internal cytoskeleton of cells and enables them to migrate, divide, and repair damaged tissue. When tissue is injured, repair cells need to migrate to the injury site and proliferate to rebuild what was damaged. TB-500 research suggests it may facilitate this process by promoting actin polymerization at wound sites, which directly enables the cellular movement required for tissue repair to occur.
TB-500 is also studied for its effects on angiogenesis , the growth of new blood vessels into damaged tissue. Adequate blood supply is critical for healing: new vessels deliver oxygen, nutrients, and immune cells to the repair site. Studies indicate TB-500 may upregulate vascular endothelial growth factor (VEGF) and related signaling pathways that drive this process.
Think of it as helping the body's repair crew get to the job site faster and ensuring the supply lines that support their work are established quickly.
Its effects on cardiac tissue have drawn particular research interest , studies in rodent models suggest it may support the survival and recruitment of cardiac progenitor cells following ischemic injury, which has made it a subject of cardiomyocyte repair research.
What the research shows.
TB-500 research is primarily preclinical , conducted in rodent and equine models where findings consistently show accelerated wound healing, tendon and ligament repair, angiogenesis, and cardiac tissue recovery following injury. The equine research base is particularly extensive: TB-500 has been studied and used in horse racing contexts for injury recovery and performance, providing a substantial body of veterinary literature beyond the rodent studies.
Human clinical trial data is minimal. No large randomized controlled trials in humans have been published as of 2025. The biological mechanisms are well understood and biologically plausible , the role of actin regulation and VEGF signaling in tissue repair is not disputed , but the translation from animal to human remains unestablished at a clinical evidence level.
The research profile is similar to BPC-157: strong, reproducible preclinical data across multiple animal species and models, high mechanistic plausibility, but an absence of human RCT evidence. This creates genuine scientific interest alongside genuine uncertainty about human application.
Biomarkers to review first.
Research protocols for TB-500 typically reference the following biomarkers as baseline context. Testing these before exploring this peptide gives you and your healthcare provider the most relevant starting information.
What it's commonly researched with.
TB-500 is frequently studied alongside BPC-157 in preclinical recovery research, where the two compounds are examined for potentially complementary tissue repair mechanisms. The combinations below represent what appears in research literature , not recommendations for use.
Goals & biomarkers connected to this peptide.
📄 Deep Dive: Read the full research overview for TB-500 including study breakdowns, research limitations, and FDA review context.
Read the TB-500 Research Overview